bioRxiv Science⌕ Search

Biology subjects

Sighel, D.

Publications and source records attributed to Sighel, D..

2 recordsLinked to original sources

Unveiling Oligodendrocyte-Lineage Differentiation in the Glioblastoma Infiltrative Zone Through Spatial Transcriptomics

IDH-wildtype glioblastoma (GBM) is the most aggressive primary brain tumor, characterized by limited therapeutic options and inevitable recurrence. This recurrence is driven by the highly infiltrative behavior of GBM cells, which prevents complete resection. Here, we performed spatially resolved transcriptomic profiling of four surgically defined GBM regions to characterize the infiltrative tumor compartment. Across multiple datasets and profiling approaches, the infiltrative zone showed reduced cellular heterogeneity compared with the tumor core. By comparison with an integrated reference of single-cell RNA sequencing data, we revealed that this reduction reflects a preferential differentiation of infiltrative GBM cells toward an oligodendrocyte-like lineage, accompanied by attenuated inflammatory signaling. In contrast, necrotic and proliferative regions display pronounced astrocyte-like and mesenchymal-like programs. Combined immunohistochemistry and fluorescence in situ hybridization confirmed the enrichment of oligodendrocyte-like tumor cells in the infiltrative area. Together, these findings identify the oligodendrocyte-like state as a defining feature and potential therapeutic vulnerability of infiltrative GBM driving brain invasion and relapse.

cancer biology↗

The three YTHDF paralogs and VIRMA are the major tumor drivers among the m6A core genes in a pan-cancer analysis

N6-methyladenosine (m6A) is the most abundant internal modification in mRNAs. Despite accumulating evidence for the profound impact of m6A on cancer biology, there are conflicting reports that alterations in genes encoding the m6A machinery proteins can either promote or suppress cancer, even in the same tumor type. Using data from The Cancer Genome Atlas, we performed a pan-cancer investigation of 15 m6A core factors in nearly 10,000 samples from 31 tumor types to reveal underlying cross-tumor patterns. Altered expression, largely driven by copy number variations at the chromosome arm level, results in the most common mode of dysregulation of these factors. YTHDF1, YTHDF2, YTHDF3, and VIRMA are the most frequently altered factors and the only ones to be uniquely altered when tumors are grouped according to the expression pattern of the m6A factors. These genes are also the only ones with coherent, pan-cancer predictive power for progression-free survival. On the contrary, METTL3, the most intensively studied m6A factor as a cancer target, shows much lower levels of alteration and no predictive power for patient survival. Therefore, we propose the non-enzymatic YTHDF and VIRMA genes as preferred subjects to dissect the role of m6A in cancer and as priority cancer targets. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=99 SRC="FIGDIR/small/598899v1_ufig1.gif" ALT="Figure 1"> View larger version (28K): org.highwire.dtl.DTLVardef@1e39eeborg.highwire.dtl.DTLVardef@d6628dorg.highwire.dtl.DTLVardef@e048a6org.highwire.dtl.DTLVardef@c19812_HPS_FORMAT_FIGEXP M_FIG C_FIG

cancer biology↗